{"id":"sinovac","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Sinovac","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:15:38.523150+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:15:58.548617+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:15:50.163716+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sinovac","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:15:50.827079+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Sinovac, marketed by the Albert B. Sabin Vaccine Institute, holds a significant position in its therapeutic area, though specific revenue figures are not provided. The drug's key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential market protection. However, the lack of detailed information on its mechanism, primary indication, and key trial results poses a significant risk in understanding its full competitive landscape and potential market threats.","ecosystem":[],"_scrapedAt":"2026-03-27T23:37:44.693Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:15:58.549137+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07473427","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-05-01","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07475000","phase":"PHASE3","title":"Second Dose of Varicella Vaccine in Healthy Children","status":"RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-01-28","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT04992195","phase":"","title":"Impact of COVID-19 Vaccines on Cerebrovascular Health","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2021-07-05","conditions":"Stroke, Stroke, Acute, Stroke, Ischemic","enrollment":500},{"nctId":"NCT07418229","phase":"PHASE1","title":"Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-09","conditions":"RSV, mRNA Vaccine","enrollment":60},{"nctId":"NCT07416110","phase":"PHASE3","title":"Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-04","conditions":"Rabies (Healthy Volunteers)","enrollment":912},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT06617715","phase":"PHASE3","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-10-23","conditions":"Pneumococcal Infectious Disease","enrollment":3080},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT07357545","phase":"PHASE3","title":"Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-08-27","conditions":"Rabies (Healthy Volunteers)","enrollment":2040},{"nctId":"NCT06063057","phase":"PHASE1, PHASE2","title":"Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-20","conditions":"Hand, Foot and Mouth Disease, Herpangina","enrollment":744},{"nctId":"NCT07300644","phase":"PHASE2","title":"Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-11-25","conditions":"Pneumococcal Infectious Disease","enrollment":420},{"nctId":"NCT07055893","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies (Healthy Volunteers)","enrollment":390},{"nctId":"NCT07055880","phase":"PHASE2","title":"Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-07-28","conditions":"Rabies","enrollment":120},{"nctId":"NCT07055295","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies","enrollment":390},{"nctId":"NCT05727215","phase":"PHASE2","title":"Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2023-02-28","conditions":"COVID-19","enrollment":150},{"nctId":"NCT05525208","phase":"PHASE2","title":"Booster Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-09-01","conditions":"COVID-19","enrollment":696},{"nctId":"NCT06474377","phase":"PHASE1","title":"Clinical Trial of PCV24 in Adults","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-06-21","conditions":"Pneumococcal Infectious Disease","enrollment":170},{"nctId":"NCT06346834","phase":"PHASE4","title":"Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2024-05-20","conditions":"Poliomyelitis","enrollment":200},{"nctId":"NCT05043259","phase":"PHASE1, PHASE2","title":"Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-08-14","conditions":"COVID-19","enrollment":423},{"nctId":"NCT05204589","phase":"PHASE3","title":"Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-01-22","conditions":"COVID-19","enrollment":10285},{"nctId":"NCT05303584","phase":"PHASE4","title":"Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-04-23","conditions":"COVID-19","enrollment":362},{"nctId":"NCT05095701","phase":"PHASE4","title":"An Immunity Persistence Study of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-12-18","conditions":"Varicella","enrollment":703},{"nctId":"NCT06482216","phase":"","title":"Correlation of Protection Against Varicella in an Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-10-10","conditions":"Varicella","enrollment":400},{"nctId":"NCT05599555","phase":"","title":"Community-based Sero-epidemiological Study of COVID-19","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2022-04-28","conditions":"COVID-19","enrollment":9600},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT06690515","phase":"PHASE1, PHASE2","title":"Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants","status":"NOT_YET_RECRUITING","sponsor":"PT Bio Farma","startDate":"2025-03-01","conditions":"Vaccine Adverse Reaction, Vaccine Reaction","enrollment":465},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT04611243","phase":"","title":"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2020-05-22","conditions":"Lung Function, Exercise Capacity, Quality of Life","enrollment":700},{"nctId":"NCT06049940","phase":"PHASE3","title":"Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-09-01","conditions":"Tetanus","enrollment":1260},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":"COVID-19","enrollment":1750},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT05230940","phase":"PHASE2","title":"Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-02-18","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":1},{"nctId":"NCT04582344","phase":"PHASE3","title":"Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-09-14","conditions":"COVID-19","enrollment":10214},{"nctId":"NCT05863429","phase":"","title":"Observational National Vaccine Study","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-05-18","conditions":"COVID-19 Infection","enrollment":200},{"nctId":"NCT05386810","phase":"PHASE3","title":"Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-11-05","conditions":"Poliomyelitis","enrollment":1572},{"nctId":"NCT04754698","phase":"PHASE4","title":"COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-02-09","conditions":"Rheumatic Disease, HIV Infections, AIDS","enrollment":2196},{"nctId":"NCT05897190","phase":"PHASE1","title":"Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster","status":"COMPLETED","sponsor":"Argorna Pharmaceuticals Co., LTD","startDate":"2022-05-16","conditions":"SARS-CoV-2","enrollment":60},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT04942405","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-06-21","conditions":"Covid19","enrollment":1290},{"nctId":"NCT05077176","phase":"PHASE3","title":"Phase 3 Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-10-08","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":4340},{"nctId":"NCT04898946","phase":"","title":"Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong","status":"COMPLETED","sponsor":"Hong Kong Sanatorium & Hospital","startDate":"2021-03-07","conditions":"Covid-19 Vaccine","enrollment":480},{"nctId":"NCT04456595","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2020-07-21","conditions":"COVID-19","enrollment":12688},{"nctId":"NCT04747821","phase":"PHASE4","title":"An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-02-07","conditions":"Covid19","enrollment":27711},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT04800133","phase":"PHASE2","title":"Covid-19 Vaccination in Adolescents and Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-05-08","conditions":"Covid19","enrollment":1018},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT04979949","phase":"PHASE2","title":"Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-07-12","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":222},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05112913","phase":"PHASE4","title":"Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-27","conditions":"COVID-19","enrollment":2520},{"nctId":"NCT05329038","phase":"PHASE4","title":"Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2022-04-19","conditions":"COVID-19","enrollment":180},{"nctId":"NCT05403307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2022-06-08","conditions":"COVID-19","enrollment":757},{"nctId":"NCT05137418","phase":"PHASE3","title":"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-27","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04992260","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-09-10","conditions":"COVID-19","enrollment":11349},{"nctId":"NCT04993365","phase":"PHASE4","title":"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-05","conditions":"COVID-19","enrollment":520},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04551547","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2020-10-31","conditions":"COVID-19","enrollment":552},{"nctId":"NCT04911790","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-06-05","conditions":"COVID-19","enrollment":131650},{"nctId":"NCT05198336","phase":"PHASE4","title":"Immunogenicity of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-01-08","conditions":"COVID-19","enrollment":395},{"nctId":"NCT04992208","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-07-24","conditions":"COVID-19","enrollment":31041},{"nctId":"NCT05411471","phase":"PHASE2","title":"Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain","status":"COMPLETED","sponsor":"Sinovac Biotech (Hong Kong) Limited","startDate":"2022-06-08","conditions":"COVID-19","enrollment":221},{"nctId":"NCT04884685","phase":"PHASE2","title":"Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-05-03","conditions":"COVID-19","enrollment":500},{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT05731115","phase":"PHASE4","title":"Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-02-27","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT05512494","phase":"PHASE4","title":"Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-11-27","conditions":"Seasonal Influenza","enrollment":1260},{"nctId":"NCT05188677","phase":"PHASE3","title":"Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-06-13","conditions":"COVID-19","enrollment":1831},{"nctId":"NCT04993209","phase":"PHASE1","title":"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-07-09","conditions":"Coronavirus Infections, Healthy","enrollment":320},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05928455","phase":"EARLY_PHASE1","title":"The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-05-14","conditions":"COVID-19, Vaccine Reaction","enrollment":120},{"nctId":"NCT05057923","phase":"NA","title":"The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores","status":"COMPLETED","sponsor":"DreamTec Research Limited","startDate":"2021-07-10","conditions":"COVID-19 Pneumonia","enrollment":9},{"nctId":"NCT04845048","phase":"","title":"Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-10","conditions":"SARS-CoV-2 Acute Respiratory Disease","enrollment":2549},{"nctId":"NCT05228613","phase":"PHASE1","title":"Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-02-16","conditions":"COVID-19","enrollment":175},{"nctId":"NCT05156632","phase":"PHASE3","title":"Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2023-02-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05428592","phase":"PHASE3","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":1100},{"nctId":"NCT04651790","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-11-27","conditions":"Covid19, Vaccines","enrollment":2300},{"nctId":"NCT05683561","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-01-25","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":6000},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05433272","phase":"PHASE3","title":"Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated","status":"UNKNOWN","sponsor":"Sinovac Biotech (Colombia) S.A.S.","startDate":"2023-08-10","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05664919","phase":"NA","title":"Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2022-10-30","conditions":"COVID-19","enrollment":7000},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05667714","phase":"NA","title":"Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2022-11-26","conditions":"COVID-19","enrollment":2900},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05583357","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2022-08-15","conditions":"COVID-19 Pandemic","enrollment":40},{"nctId":"NCT05109559","phase":"PHASE1, PHASE2","title":"Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-12-20","conditions":"SARS-CoV-2 Infection","enrollment":690},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT04974164","phase":"","title":"Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-08-17","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT04952727","phase":"PHASE4","title":"Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-08-26","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05148949","phase":"PHASE4","title":"Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-12-22","conditions":"COVID-19, Pulmonary Tuberculosis","enrollment":240},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT04989465","phase":"PHASE4","title":"A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-09-10","conditions":"Pneumococcal Infections","enrollment":600},{"nctId":"NCT05165966","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-10-20","conditions":"COVID-19","enrollment":340},{"nctId":"NCT04383574","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2020-05-22","conditions":"COVID-19","enrollment":422},{"nctId":"NCT05398926","phase":"PHASE4","title":"Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-12-06","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05107557","phase":"PHASE4","title":"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-11-05","conditions":"COVID-19","enrollment":520}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"COVID-19"},{"count":3,"reaction":"COVID-19 PNEUMONIA"},{"count":2,"reaction":"VARICELLA ZOSTER VIRUS INFECTION"},{"count":1,"reaction":"ACUTE RESPIRATORY FAILURE"},{"count":1,"reaction":"CHOLELITHIASIS"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"HERPES VIRUS INFECTION"},{"count":1,"reaction":"HYPOAESTHESIA"},{"count":1,"reaction":"MUSCULAR WEAKNESS"},{"count":1,"reaction":"MYALGIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":471,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Sinovac","genericName":"Sinovac","companyName":"Albert B. Sabin Vaccine Institute","companyId":"albert-b-sabin-vaccine-institute","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:15:58.549137+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}